Unknown

Dataset Information

0

Frequent hepatitis B virus rebound among HIV-hepatitis B virus-coinfected patients following antiretroviral therapy interruption.


ABSTRACT: The impact of antiretroviral therapy (ART) interruption in HIV-hepatitis B virus (HBV)-coinfected patients was examined in the Strategic Management of AntiRetroviral Therapy (SMART) study.Plasma HBV DNA was measured in all hepatitis B surface antigen-positive (HBV-positive) participants at baseline, and at months 1, 2, 4, 6, 8, 10, and 12.Among HBV-positive participants in the ART interruption (drug conservation) (n = 72) and ART continuation (virological suppression) (n = 62) arms, HBV DNA rebound of more than 1 log from baseline at months 1-4 was seen in 31-33% (P = 0.003) and 3-4% (P = 0.017), respectively. Thirteen HBV-positive participants had HBV DNA rebound of more than 3 log, including 12 in the drug conservation arm, of which eight were on tenofovir-containing regimens. Factors independently associated with a HBV DNA rebound were drug conservation arm (P = 0.0002), nondetectable HBV DNA at baseline (P = 0.007), and black race (P = 0.03). Time to ART reinitiation was shorter (7.5, 15.6, and 17.8 months; P < 0.0001) and proportion reinitiating greater (62.5, 46.5, and 39.7%; P = 0.0002) among HBV-positive participants as compared with hepatitis C virus-positive and non-HBV/hepatitis C virus participants in the drug conservation arm. No hepatic decompensation events occurred among HBV-positive participants in either arm.HBV DNA rebound following ART interruption is common and may be associated with accelerated immune deficiency in HIV-HBV-coinfected patients.

SUBMITTER: Dore GJ 

PROVIDER: S-EPMC2881334 | biostudies-literature | 2010 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications

Frequent hepatitis B virus rebound among HIV-hepatitis B virus-coinfected patients following antiretroviral therapy interruption.

Dore Gregory J GJ   Soriano Vicente V   Rockstroh Jürgen J   Kupfer Bernd B   Tedaldi Ellen E   Peters Lars L   Neuhaus Jacqueline J   Puoti Massimo M   Klein Marina B MB   Mocroft Amanda A   Clotet Bonaventura B   Lundgren Jens D JD  

AIDS (London, England) 20100301 6


<h4>Background</h4>The impact of antiretroviral therapy (ART) interruption in HIV-hepatitis B virus (HBV)-coinfected patients was examined in the Strategic Management of AntiRetroviral Therapy (SMART) study.<h4>Methods</h4>Plasma HBV DNA was measured in all hepatitis B surface antigen-positive (HBV-positive) participants at baseline, and at months 1, 2, 4, 6, 8, 10, and 12.<h4>Results</h4>Among HBV-positive participants in the ART interruption (drug conservation) (n = 72) and ART continuation (v  ...[more]

Similar Datasets

| S-EPMC11309407 | biostudies-literature
| S-EPMC5072458 | biostudies-literature
| S-EPMC7375368 | biostudies-literature
| S-EPMC8748440 | biostudies-literature
| S-EPMC3922212 | biostudies-literature
| S-EPMC4847932 | biostudies-literature
| S-EPMC10985789 | biostudies-literature
| S-EPMC9468877 | biostudies-literature
| S-EPMC4943732 | biostudies-literature
| S-EPMC5500350 | biostudies-literature